CSL, Selexis ink commercial license agreement
Australia-based CSL has entered into a commercial license agreement with Selexis, headquartered in Switzerland, for the pre-clinical development of a therapeutic antibody anticipated to enter phase I clinical trials in 2012. This commercial license agreement provides CSL with the rights to use a cell line, generated using the Selexis SUREtechnology Platform, for the cGMP production of an undisclosed antibody.
"We are pleased CSL is moving forward with a production cell line generated using the SUREtechnology Platform," said Dr. Igor Fisch, CEO, Selexis. "This agreement represents Selexis' commitment to helping our clients bring biologic therapeutic drugs into the clinic. We look forward to continuing to work with CSL."